Premium
Lamotrigine‐Associated Rash: Risk/Benefit Considerations in Adults and Children
Author(s) -
Guberman Alan H.,
Besag Frank M. C.,
Brodie Martin J.,
Dooley Joseph M.,
Duchowny Michael S.,
Pellock John M.,
Richens Alan,
Stern Robert S.,
Trevathan Edwin
Publication year - 1999
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1999.tb00807.x
Subject(s) - lamotrigine , rash , medicine , dosing , incidence (geometry) , adverse effect , population , anticonvulsant , pediatrics , intensive care medicine , dermatology , epilepsy , psychiatry , physics , environmental health , optics
Summary:Purpose: Lamotrigine (LTG) is an antiepileptic drug (AED) recently released in several countries. It is effective for a variety of seizure types in adults and children both as an add‐on agent and in monotherapy, and is generally well tolerated. This report reviews the apparent risk factors for rash associated with LTG to determine whether and how the risk of serious rash can be minimized in practice. Methods: The panel of experts reviewed all published and unpublished data related to the incidence and risk factors for serious rash with LTG. Results: An allergic skin reaction occurs in ∼10% of patients, usually in the first 8 weeks. Rashes leading to hospitalization, including Stevens—Johnson syndrome and hypersensitivity syndrome, occurred in approximately one of 300 adults and one of 100 children in clinical trials and appeared to be increased with overrapid titration when starting therapy and with concurrent valproate (VPA). Conclusions: Recommendations are made for both minimizing the likelihood of serious rash and for management of rash in patients taking LTG. Risk of serious rash may possibly be lessened by strict adherence to manufacturer's dosing guidelines, particularly in patients who are at higher risk: those on concurrent VPA and in the pediatric population.